These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2511177)

  • 1. T-cell phenotype is associated with decreased survival in non-Hodgkin's lymphoma.
    Shimizu K; Hamajima N; Ohnishi K; Hara K; Kunii A
    Jpn J Cancer Res; 1989 Aug; 80(8):720-6. PubMed ID: 2511177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the spectrum of postthymic T-cell malignancies in Taiwan. A clinicopathologic study of HTLV-1-positive and HTLV-1-negative cases.
    Su IJ; Wang CH; Cheng AL; Chen YC; Hsieh HC; Chen CJ; Tien HF; Woei-Tsay ; Huang SS; Hu CY
    Cancer; 1988 May; 61(10):2060-70. PubMed ID: 2896068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
    Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
    Chubachi A; Miura AB; Yamaguchi A; Nishimura S
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
    J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical and immunological study on non-Hodgkin's malignant lymphoma in nasosinus region].
    Uchizono A; Fukuda K; Itoh K; Ushikai M; Ohyama M
    Nihon Jibiinkoka Gakkai Kaiho; 1990 Apr; 93(4):554-65. PubMed ID: 2376791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model for aggressive non-Hodgkin's lymphoma.
    International Non-Hodgkin's Lymphoma Prognostic Factors Project
    N Engl J Med; 1993 Sep; 329(14):987-94. PubMed ID: 8141877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors of invasive non-Hodgkin's lymphoma].
    Yu H; Hong XN; Li J; Peng LP; Ye L
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):461-3. PubMed ID: 17974284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
    Conlan MG; Bast M; Armitage JO; Weisenburger DD
    J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis].
    Okabe K; Toki H; Kimura Y; Fujii M; Kiura K; Moriwaki S
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2960-4. PubMed ID: 3490224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
    Bai CM; Yang T; Xü Y; Zhang W; Liu XL; Zhu YL; Chen SC; Shen T
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?
    Cheng AL; Chen YC; Wang CH; Su IJ; Hsieh HC; Chang JY; Hwang WS; Su WC; Liu TW; Tien HF
    J Clin Oncol; 1989 Jun; 7(6):725-31. PubMed ID: 2654330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
    Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
    J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
    Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
    Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.